Thermo Fisher Scientific launches PPD CorEvitas Chronic Hand Eczema Registry
New registry will generate robust real-world evidence on disease burden, treatment patterns, and long-term effectiveness of newly approved and emerging therapies
12 Jun 2026Product news
Thermo Fisher Scientific has launched the PPD™ CorEvitas™ Chronic Hand Eczema Registry, a prospective, observational cohort registry in North America designed to generate regulatory-grade, real-world evidence on chronic hand eczema.
The registry will capture how patients with chronic hand eczema are treated in routine clinical care, why the disease imposes a significant burden on quality of life and work productivity, and how newly approved and emerging therapies perform over time.
New North American registry focused on chronic hand eczema
The PPD CorEvitas Chronic Hand Eczema Registry is open to enrollment across North America. As part of the CorEvitas Clinical Registries portfolio, it will feature primary collection of proprietary, prospectively collected clinical data to support evaluation of disease history, treatment patterns, comorbidities and the long-term effectiveness of therapies used to treat chronic hand eczema.
The registry is designed to support clinicians, dermatology researchers, and biopharma and biotech sponsors seeking longitudinal evidence on chronic hand eczema treatment patterns, disease burden and long-term effectiveness outcomes in real-world clinical practice.
Real-world evidence to support regulatory and clinical decision-making
CorEvitas Clinical Registries are proprietary multi-drug disease registries conducting primary data collection of disease activity and treatment outcome measures to support regulatory-grade evidence needs and inform regulator and clinical stakeholder decision-making.
The PPD CorEvitas Chronic Hand Eczema Registry addresses the need for robust real-world evidence on chronic hand eczema, including how the condition progresses, how patients are treated in routine care and how current and emerging therapies perform over time.
Longitudinal real-world data from the registry are intended to improve understanding of disease burden and support evidence generation for treatment decision-making and regulatory research needs.
“Chronic hand eczema can be difficult to manage because symptoms often persist due to occupational exposures, affecting patients’ day-to-day activities, work productivity and quality of life,” said Dr. Peter Wahl, vice president and global head of scientific affairs for PPD CorEvitas Clinical Registries.
“A unique feature of this registry is collection of patient-reported symptoms, treatment experience and quality of life and work productivity at 7 days and 30 days post-drug initiation, capturing the patient’s perspective on rapid response to a new treatment.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
What is the PPD CorEvitas Chronic Hand Eczema Registry and how does Thermo Fisher Scientific use it to generate real-world evidence?
The PPD™ CorEvitas™ Chronic Hand Eczema Registry, launched by Thermo Fisher Scientific, is a prospective, observational cohort registry in North America. It collects proprietary, prospectively gathered clinical data on chronic hand eczema, including disease history, treatment patterns, comorbidities and long-term therapy effectiveness, to generate regulatory-grade, real-world evidence for clinicians, researchers, and biopharma and biotech sponsors.
How does the PPD CorEvitas Chronic Hand Eczema Registry capture patient-reported outcomes and rapid treatment response?
The PPD CorEvitas Chronic Hand Eczema Registry includes patient-reported symptoms, treatment experience, quality of life and work productivity at 7 and 30 days after drug initiation. This design captures the patient perspective on rapid response to new therapies and supports longitudinal evaluation of real-world treatment effectiveness and disease burden.
Why does the registry matter?
Chronic hand eczema can affect daily activities, work productivity and quality of life. Longitudinal real-world data can help improve understanding of disease burden and support evidence generation for treatment decision-making and regulatory research needs.